| HOME >> BIOLOGY >> TECHNOLOGY |
2008 2007 2008 2007
Revenues $ - $ - $ - $ -
Operating costs and
expenses:
Research and
development 1,902,144 1,002,780 2,986,503 1,815,300
General and
administrative 561,533 434,208 1,201,206 1,118,834
Total operating
costs and expenses 2,463,677 1,436,988 4,187,709 2,934,134
Loss from operations (2,463,677) (1,436,988) (4,187,709) (2,934,134)
Interest income 86,237 228,858 226,222 473,926
Loss before income
taxes (2,377,440) (1,208,130) (3,961,487) (2,460,208)
Provision for income
taxes - - - -
Net loss $(2,377,440) $(1,208,130)$(3,961,487) $(2,460,208)
Loss per share - basic
and diluted $(0.19) $(0.10) $(0.32) $(0.20)
Weighted average shares
outstanding - basic and
diluted 12,567,226 12,527,564 12,560,085 12,523,210
CATALYST PHARMACEUTICAL PARTNERS, INC.
(a development stage company)
CONDENSED BALANCE SHEETS
June 30, December 31,
2008 2007
(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents $13,084,108 $15,943,896
Interest receivable 24,167 63,709
Prepaid expenses 288,318 524,081
Total current asse
'/>"/>
| SOURCE Catalyst Pharmaceutical Partners, Inc. Copyright©2008 PR Newswire. All rights reserved |